RxDoctor Payments Data

Nikki Bonhaus, DO

Hospitalist · Florence, KYNPI 1194187641

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 27.6% of the total. Among hospitalist clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$863in general payments, 2019–2025

Across 51 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$238
  • Lilly USA, LLC$127
  • Novo Nordisk$110
  • Johnson & Johnson$62
  • Merck$40
  • Radius Health, Inc.$39
  • plus $247 from 11 others

What the payments were for

  • Food & beverage$83997%
  • Education$243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$863 in reported general payments places this provider in the 90th percentile of 258 hospitalist providers in Kentucky.

See all hospitalist providers in Kentucky

Medicare billing

Part B allowed, 2024
$101,684
Medicare patients
290
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$12,599
Potassium Chloride15$1,216
Albuterol Sulfate HfaAlbuterol Sulfate16$372
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$336
Cefdinir57$309
Fluconazole14$193
Pantoprazole Sodium23$190
Atorvastatin Calcium26$145
Metoprolol Succinate17$139
Prednisone52$132
Torsemide14$123
Amlodipine Besylate33$84
Doxycycline Hyclate16$71
Klor-Con M20Potassium Chloride11$66
Spironolactone15$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$12,59924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 hospitalist providers in Kentucky.

Other hospitalist in Florence

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →